John E. Godwin

6.5k total citations · 2 hit papers
110 papers, 4.1k citations indexed

About

John E. Godwin is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, John E. Godwin has authored 110 papers receiving a total of 4.1k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Hematology, 37 papers in Oncology and 31 papers in Molecular Biology. Recurrent topics in John E. Godwin's work include Acute Myeloid Leukemia Research (59 papers), CAR-T cell therapy research (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). John E. Godwin is often cited by papers focused on Acute Myeloid Leukemia Research (59 papers), CAR-T cell therapy research (19 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (13 papers). John E. Godwin collaborates with scholars based in United States, France and Israel. John E. Godwin's co-authors include Frederick R. Appelbaum, Cheryl L. Willman, David R. Head, Marilyn L. Slovak, Stephen H. Petersdorf, Jeanne E. Anderson, Kenneth J. Kopecky, Holly Gundacker, Catherine P. Leith and Sucha Nand and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of the American College of Cardiology.

In The Last Decade

John E. Godwin

107 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Age and acute myeloid leukemia

2006 982 citations Frederick R. Appelbaum, David R. Head et al. Blood profile →
Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

1997 696 citations Kenneth J. Kopecky, John E. Godwin et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
John E. Godwin United States	28	2.6k	1.6k	1.3k	922	764	110	4.1k
Daniela Cilloni Italy	33	2.7k 1.0×	1.6k 1.0×	848 0.7×	783 0.8×	1.6k 2.1×	181	4.4k
Martha Arellano United States	27	2.6k 1.0×	2.0k 1.2×	848 0.7×	870 0.9×	720 0.9×	119	4.4k
R Ohno Japan	33	4.1k 1.6×	2.2k 1.3×	1.2k 0.9×	1.3k 1.4×	1.1k 1.5×	104	5.7k
Vikram Mathews India	36	2.6k 1.0×	1.6k 1.0×	678 0.5×	702 0.8×	877 1.1×	293	4.0k
Felicetto Ferrara Italy	37	3.9k 1.5×	2.6k 1.6×	1.1k 0.9×	1.6k 1.7×	1.0k 1.3×	196	5.7k
Susan O’Brien United States	29	2.2k 0.9×	949 0.6×	575 0.5×	686 0.7×	1.3k 1.6×	69	3.1k
Ollivier Legrand France	31	1.5k 0.6×	1.3k 0.8×	1.5k 1.2×	567 0.6×	439 0.6×	93	3.2k
Yasushi Miyazaki Japan	34	2.3k 0.9×	1.4k 0.9×	790 0.6×	969 1.1×	738 1.0×	254	5.0k
Virginia M. Klimek United States	26	2.8k 1.1×	3.1k 1.9×	871 0.7×	537 0.6×	981 1.3×	78	5.1k
Stéphane de Botton France	44	4.1k 1.6×	3.0k 1.9×	1.2k 0.9×	997 1.1×	1.3k 1.8×	201	6.2k

Countries citing papers authored by John E. Godwin

Since Specialization

Citations

This map shows the geographic impact of John E. Godwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Godwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Godwin more than expected).

Fields of papers citing papers by John E. Godwin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Godwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Godwin. The network helps show where John E. Godwin may publish in the future.

Co-authorship network of co-authors of John E. Godwin

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Godwin. A scholar is included among the top collaborators of John E. Godwin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Godwin. John E. Godwin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Algazi, Alain P., James Moon, Christopher D. Lao, et al.. (2024). A phase 1 study of triple‐targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF‐mutated cancers. Cancer. 130(10). 1784–1796. 6 indexed citations

Othus, Megan, Rhonda E. Ries, Jasmine Naru, et al.. (2024). Evaluation of ELN2022 Risk Stratification in NPM1 Mutated AML: A Study from the Fred Hutch and SWOG. Blood. 144(Supplement 1). 4309–4309.

Godwin, John E., César O. Freytes, Michael B. Maris, et al.. (2021). Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) at Nonuniversity Medical Centers (NMCs): Initial Results from the Outreach Study in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL). Transplantation and Cellular Therapy. 27(3). S203–S204. 1 indexed citations

Othus, Megan, Guillermo Garcia‐Manero, John E. Godwin, et al.. (2019). Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data. Blood. 134(Supplement_1). 291–291. 1 indexed citations

Foran, James M., Zhuoxin Sun, David F. Claxton, et al.. (2019). Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study. Blood. 134(Supplement_1). 115–115. 24 indexed citations

Foran, James M., Zhuoxin Sun, Elisabeth Paietta, et al.. (2018). FLT3-ITD Mutations Are Prevalent and Significantly Impact Outcome after Intensive Therapy in Elderly Adults with Acute Myeloid Leukemia (AML): Analysis of the North American Intergroup E2906 Phase III Trial in Patients Age ≥60 Years. Blood. 132(Supplement 1). 3995–3995. 4 indexed citations

Pogosova‐Agadjanyan, Era L., Anna Moseley, Megan Othus, et al.. (2017). Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. Biopreservation and Biobanking. 16(1). 42–52. 6 indexed citations

Othus, Megan, Guillermo Garcia‐Manero, John E. Godwin, et al.. (2017). Associations between Complete Remissions (CRs) with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia and 2-3 Year Survival (“Potential Cure”) over the Past Four Decades: Analysis of SWOG Trial Data. Blood. 130. 1301–1301. 1 indexed citations

Rettig, Michael P., John E. Godwin, Norbert Vey, et al.. (2017). Preliminary Translational Results from an Ongoing Phase 1 Study of Flotetuzumab, a CD123 x CD3 Dart®, in AML/MDS: Rationale for Combining Flotetuzumab and Anti-PD-1/PD-L1 Immunotherapies. Blood. 130. 1365–1365. 10 indexed citations

10.

Ostronoff, Fabiana, Megan Othus, Elihu H. Estey, et al.. (2015). Prognostic Significance of NPM1 Mutations in the Absence of FLT3 –Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report. Journal of Clinical Oncology. 33(10). 1157–1164. 96 indexed citations

11.

Godwin, John E., Izidore S. Lossos, Michael E. Williams, et al.. (2013). A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.. Journal of Clinical Oncology. 31(15_suppl). TPS3108–TPS3108. 10 indexed citations

12.

Malone, James, et al.. (2012). Cetuximab in Refractory Skin Cancer Treatment. Journal of Cancer. 3. 257–261. 42 indexed citations

13.

Nand, Sucha, John E. Godwin, Scott E. Smith, et al.. (2008). Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leukemia & lymphoma. 49(11). 2141–2147. 46 indexed citations

14.

Nand, Sucha, et al.. (2006). Azacitidine Plus Gemtuzumab Ozogamicin (GO): A Novel Combination in the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) in the Elderly.. Blood. 108(11). 1981–1981. 8 indexed citations

15.

Godwin, John E. & David Crews. (1999). Hormonal regulation of progesterone receptor mRNA expression in the hypothalamus of whiptail lizards: Regional and species differences. Journal of Neurobiology. 39(2). 287–287. 2 indexed citations

16.

Godwin, John E., et al.. (1996). Testing for Passovoy Defect in Children with Prolonged Activated Partial Thromboplastin Time (APTT). Journal of Pediatric Hematology/Oncology. 18(3). 262–265. 2 indexed citations

17.

Nand, Sucha, Wendy Stock, John E. Godwin, & Susan G. Fisher. (1996). Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. American Journal of Hematology. 52(1). 42–46. 91 indexed citations

18.

Oskarsson, Helgi, John E. Godwin, Rolf M. Gunnar, & J. X. Thomas. (1993). Dietary fish oil supplementation reduces myocardial infarct size in a canine model of ischemia and reperfusion. Journal of the American College of Cardiology. 21(5). 1280–1285. 35 indexed citations

19.

Elias, Laurence, Donna Stock-Novack, David R. Head, et al.. (1993). A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.. PubMed. 7(3). 361–5. 55 indexed citations

20.

Nand, Sucha & John E. Godwin. (1988). Hypoplastic myelodysplastic syndrome. Cancer. 62(5). 958–964. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact